Aileron Therapeutics Inc (NASDAQ:ALRN) Director Rickenbach Josef H. Von acquired 113,145 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were purchased at an average price of $0.98 per share, with a total value of $110,882.10.

ALRN opened at $0.92 on Friday. The firm has a market cap of $28.92 million, a P/E ratio of -0.45 and a beta of 2.31. Aileron Therapeutics Inc has a 12 month low of $0.44 and a 12 month high of $3.53. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.16. The stock has a 50-day moving average of $0.71 and a 200 day moving average of $1.12.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03). On average, research analysts forecast that Aileron Therapeutics Inc will post -1.14 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Aileron Therapeutics in a research report on Wednesday, September 11th. Finally, ValuEngine upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $4.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALRN. Jennison Associates LLC grew its position in Aileron Therapeutics by 649.6% in the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock worth $3,828,000 after acquiring an additional 1,768,073 shares in the last quarter. Vanguard Group Inc. grew its position in Aileron Therapeutics by 261.6% in the second quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock worth $240,000 after acquiring an additional 240,910 shares in the last quarter. Deutsche Bank AG grew its position in Aileron Therapeutics by 432.9% in the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock worth $108,000 after acquiring an additional 104,932 shares in the last quarter. Finally, BlackRock Inc. grew its position in Aileron Therapeutics by 179.6% in the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock worth $36,000 after acquiring an additional 31,787 shares in the last quarter. Institutional investors own 26.00% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

See Also: Gross Domestic Product (GDP)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.